Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors

References

• Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi I. Smallpox and its Eradication. World Health Organization, Geneva, Switzerland (1988).
   Google Scholar
• Bray M, Buller M. Looking back at smallpox. Clin. Infect. Dis.38(6), 882–889 (2004).
   PubMed Web of Science ®Google Scholar
• Henderson DA. Smallpox: clinical and epidemiologic features. Emerg. Infect. Dis.5(4), 537–539 (1999).
   PubMed Web of Science ®Google Scholar
• Henderson DA, Inglesby TV, Bartlett JG et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA281(22), 2127–2137 (1999).
   PubMed Web of Science ®Google Scholar
• Moore ZS, Seward JF, Lane JM. Smallpox. Lancet367(9508), 425–435 (2006).
   PubMed Web of Science ®Google Scholar
• Damon IK. Orthopoxviruses. In: Principles and Practice of Infectious Diseases, 7th Edition. Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingstone Elsevier, Philadelphia, PA, USA, 1923–1932 (2010).
   Google Scholar
• WHO recommendations concerning the distribution, handling and synthesis of variola virus DNA, May 2008. Wkly Epidemiol. Rec.83(44), 393–395 (2008).
   PubMedGoogle Scholar
• Breman JG, Henderson DA. Diagnosis and management of smallpox. N. Engl. J. Med.346(17), 1300–1308 (2002).
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Fritz EA, Hensley LE. Countermeasures to the bioterrorist threat of smallpox. Curr. Mol. Med.5(8), 817–826 (2005).
   PubMedGoogle Scholar
• Bicknell WJ. The case for voluntary smallpox vaccination. N. Engl. J. Med.346(17), 1323–1325 (2002).
   PubMed Web of Science ®Google Scholar
• Breman JG, Arita I, Fenner F. Preventing the return of smallpox. N. Engl. J. Med.348(5), 463–466 (2003).
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Boer R, Bhatnagar V et al. A model for a smallpox vaccination policy. N. Engl. J. Med.348(5), 416–425 (2003).
   PubMed Web of Science ®Google Scholar
• Meltzer MI, Damon I, LeDuc JW, Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis.7(6), 959–969 (2001).
   PubMed Web of Science ®Google Scholar
• Weiss MM, Weiss PD, Mathisen G, Guze P. Rethinking smallpox. Clin. Infect. Dis.39(11), 1668–1673 (2004).
   PubMedGoogle Scholar
• Mack T. A Different view of smallpox and vaccination. N. Engl. J. Med.348(5), 460–463 (2003).
   PubMed Web of Science ®Google Scholar
• Lane JM, Goldstein J. Evaluation of 21st Century risks of smallpox vaccination and policy options. Ann. Intern. Med.138(6), 488–493 (2003).
   PubMed Web of Science ®Google Scholar
• LeDuc JW, Damon I, Relman DA, Huggins J, Jahrling PB. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg. Infect. Dis.8(7), 743–745 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL. Developing new smallpox vaccines. Emerg. Infect. Dis.7(6), 920–926 (2001).
   PubMed Web of Science ®Google Scholar
• Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am. J. Epidemiol.93(4), 238–240 (1971).
   PubMed Web of Science ®Google Scholar
• Lane JM, Millar JD, Neff JM. Smallpox and smallpox vaccination policy. Annu. Rev. Med.22, 251–272 (1971).
   PubMedGoogle Scholar
• O’Connell CJ, Karzon DT, Barron AL, Plaut ME, Ali VM. Progressive vaccinia with normal antibodies. A case possibly due to deficient cellular immunity. Ann. Intern. Med.60, 282–289 (1964).
   PubMedGoogle Scholar
• Casey C, Vellozzi C, Mootrey GT et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm. Rep.55(RR-1), 1–16 (2006).
   PubMedGoogle Scholar
• Freed ER, Duma RJ, Escobar MR. Vaccinia necrosum and its relationship to impaired immunologic responsiveness. Am. J. Med.52(3), 411–420 (1972).
   PubMedGoogle Scholar
• Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med.316(11), 673–676 (1987).
   PubMed Web of Science ®Google Scholar
• Aragon TJ, Ulrich S, Fernyak S, Rutherford GW. Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963–1968. BMC Public Health3, 26 (2003).
   PubMedGoogle Scholar
• Casey CG, Iskander JK, Roper MH et al. Adverse events associated with smallpox vaccination in the United States, January–October 2003. JAMA294(21), 2734–2743 (2005).
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA289(24), 3278–3282 (2003).
   PubMed Web of Science ®Google Scholar
• Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine23(17–18), 2078–2081 (2005).
   PubMed Web of Science ®Google Scholar
• Update: adverse events following civilian smallpox vaccination – United States, 2003. MMWR Morb. Mortal. Wkly Rep.53(5), 106–107 (2004).
   PubMedGoogle Scholar
• Morgan J, Roper MH, Sperling L et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January–October 2003. Clin. Infect. Dis.46(Suppl. 3), S242–S250 (2008).
   PubMed Web of Science ®Google Scholar
• Swerdlow DL, Roper MH, Morgan J et al. Ischemic cardiac events during the Department of Health and Human Services Smallpox Vaccination Program, 2003. Clin. Infect. Dis.46(Suppl. 3), S234–241 (2008).
   Google Scholar
• Halsell JS, Riddle JR, Atwood JE et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA289(24), 3283–3289 (2003).
   PubMed Web of Science ®Google Scholar
• Bray M, Wright ME. Progressive vaccinia. Clin. Infect. Dis.36(6), 766–774 (2003).
   PubMed Web of Science ®Google Scholar
• Nell P, Kohl KS, Graham PL et al. Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine25(31), 5735–5744 (2007).
   PubMedGoogle Scholar
• Engler RJM, Kenner J, Leung DYM. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J. Allergy Clin. Immunol.110(3), 357–365 (2002).
   PubMedGoogle Scholar
• Nell P, Kohl KS, Graham PL et al. Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine25(31), 5725–5734 (2007).
   PubMedGoogle Scholar
• Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis.37(2), 251–271 (2003).
   PubMed Web of Science ®Google Scholar
• Vellozzi C, Lane JM, Averhoff F et al. Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003. Clin. Infect. Dis.41(5), 689–697 (2005).
   PubMedGoogle Scholar
• Talbot TR, Bredenberg HK, Smith M, LaFleur BJ, Boyd A, Edwards KM. Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. JAMA289(24), 3290–3294 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh SR, Johnson RP. Vaccinia folliculitis after primary dryvax vaccination. Infect. Dis. Clin. Pract.15(2), 132–134 (2007).
   Google Scholar
• Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract.5(2), 84–90 (2002).
   PubMedGoogle Scholar
• Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm. Rep.50(RR-10), 1–25 (2001).
   PubMedGoogle Scholar
• Wharton M, Strikas RA, Harpaz R et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep.52(RR-7), 1–16 (2003).
   PubMedGoogle Scholar
• Slifka MK, Hanifin JM. Smallpox: the basics. Dermatol. Clin.22(3), 263–274 (2004).
   PubMedGoogle Scholar
• Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep.52(RR-4), 1–28 (2003).
   PubMedGoogle Scholar
• Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Investig. Drugs17(4), 555–564 (2008).
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Kennedy JS, Clanton DJ et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet365(9457), 398–409 (2005).
   PubMed Web of Science ®Google Scholar
• Weltzin R, Liu J, Pugachev KV et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med.9(9), 1125–1130 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Langland JO, Kibler KV et al. Vaccinia virus vaccines: past, present and future. Antiviral Res.84(1), 1–13 (2009).
   PubMed Web of Science ®Google Scholar
• Cutchins E, Warren J, Jones WP. The antibody response to smallpox vaccination as measured by a tissue culture plaque method. J. Immunol.85, 275–283 (1960).
   PubMedGoogle Scholar
• McCarthy K, Downie AW, Bradley WH. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J. Hyg. (Lond.)56(4), 466–478 (1958).
   PubMedGoogle Scholar
• Belshe RB, Newman FK, Frey SE et al. Dose-dependent neutralizing-antibody responses to vaccinia. J. Infect. Dis.189(3), 493–497 (2004).
   PubMedGoogle Scholar
• Couch RB, Winokur P, Edwards KM et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J. Infect. Dis.195(6), 826–832 (2007).
   PubMed Web of Science ®Google Scholar
• LeDuc JW, Becher J. Current status of smallpox vaccine. Emerg. Infect. Dis.5(4), 593–594 (1999).
   PubMed Web of Science ®Google Scholar
• LeDuc JW, Jahrling PB. Strengthening national preparedness for smallpox: an update. Emerg. Infect. Dis.7(1), 155–157 (2001).
   PubMed Web of Science ®Google Scholar
• Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis.8(Suppl. 2), S31–S44 (2004).
   PubMed Web of Science ®Google Scholar
• Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine26(4), 581–588 (2008).
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Kennedy JS et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine27(10), 1637–1644 (2009).
   PubMed Web of Science ®Google Scholar
• Artenstein AW, Johnson C, Marbury TC et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine23(25), 3301–3309 (2005).
   PubMed Web of Science ®Google Scholar
• Osborne JD, Da Silva M, Frace AM et al. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine25(52), 8807–8832 (2007).
   PubMed Web of Science ®Google Scholar
• Beachkofsky TM, Carrizales SC, Bidinger JJ, Hrncir DE, Whittemore DE, Hivnor CM. Adverse events following smallpox vaccination with ACAM2000 in a military population. Arch. Dermatol.146(6), 656–661 (2010).
   PubMed Web of Science ®Google Scholar
• Mack TM, Noble J Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg.21(2), 214–218 (1972).
   PubMed Web of Science ®Google Scholar
• Sarkar J, Mitra A, Mukherjee M. The minimum protective level of antibodies in smallpox. Bull. World Health Organ.52, 307–311 (1975).
   PubMed Web of Science ®Google Scholar
• Frey SE, Couch RB, Tacket CO et al. Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med.346(17), 1265–1274 (2002).
   PubMed Web of Science ®Google Scholar
• McClain DJ, Harrison S, Yeager CL et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J. Infect. Dis.175(4), 756–763 (1997).
   PubMed Web of Science ®Google Scholar
• Wiser I, Balicer RD, Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine25(6), 976–984 (2007).
   PubMed Web of Science ®Google Scholar
• Jang HC, Kim CJ, Kim KH et al. A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. Vaccine28(36), 5845–5849 (2010).
   PubMed Web of Science ®Google Scholar
• Kim SH, Choi SJ, Park WB et al. Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine25(33), 6287–6291 (2007).
   PubMedGoogle Scholar
• Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine24(47–48), 7009–7022 (2006).
   PubMed Web of Science ®Google Scholar
• Saito T, Fujii T, Kanatani Y et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA301(10), 1025–1033 (2009).
   PubMed Web of Science ®Google Scholar
• Meseda CA, Mayer AE, Kumar A et al. Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin. Vaccine Immunol.16(9), 1261–1271 (2009).
   PubMedGoogle Scholar
• Wilck MB, Seaman MS, Baden LR et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J. Infect. Dis.201(9), 1361–1370 (2010).
   PubMed Web of Science ®Google Scholar
• Rivers TM. Cultivation of vaccine virus for Jennerian prophylaxis in man. J. Exp. Med.54(4), 453–461 (1931).
   PubMedGoogle Scholar
• Rivers TM, Ward SM. Jennerian prophylaxis by means of intradermal injections of culture vaccine virus. J. Exp. Med.62(4), 549–560 (1935).
   PubMedGoogle Scholar
• Kempe CH, Fulginiti V, Minamitani M, Shinefield H. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78). Pediatrics42(6), 980–985 (1968).
   PubMedGoogle Scholar
• Kempe CH. Smallpox vaccination of eczema patients with attenuated live vaccinia virus. Yale J. Biol. Med.41, 1–12 (1968).
   PubMedGoogle Scholar
• Jerome KR. Lennette’s Laboratory Diagnosis of Viral Infections, 4th Edition. Informa Healthcare, New York, NY, USA (2010).
   Google Scholar
• Speers WC, Wesley RB, Neff JM, Goldstein J, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. II. Clinical and serologic observations of response to revaccination with calf lymph vaccine. Pediatr. Res.9(8), 628–632 (1975).
   PubMed Web of Science ®Google Scholar
• Wesley RB, Speers WC, Neff JM, Ruben FL, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination. Pediatr. Res.9(8), 624–628 (1975).
   PubMed Web of Science ®Google Scholar
• Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology244(2), 365–396 (1998).
   PubMed Web of Science ®Google Scholar
• Mayr A. Smallpox vaccination and bioterrorism with pox viruses. Comp. Immunol. Microbiol. Infect. Dis.26(5–6), 423–430 (2003).
   PubMedGoogle Scholar
• Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol.72(5), 1031–1038 (1991).
   PubMed Web of Science ®Google Scholar
• Stittelaar KJ, Osterhaus ADME. MVA: a cuckoo in the vaccine nest? Vaccine19(27), V–VI (2001).
   PubMedGoogle Scholar
• Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev. Vaccines8(1), 13–24 (2009).
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Kennedy JS et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine25(51), 8562–8573 (2007).
   PubMed Web of Science ®Google Scholar
• Parrino J, McCurdy LH, Larkin BD et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine25(8), 1513–1525 (2007).
   PubMed Web of Science ®Google Scholar
• Vollmar J, Arndtz N, Eckl KM et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine24(12), 2065–2070 (2006).
   PubMed Web of Science ®Google Scholar
• Seaman MS, Wilck MB, Baden LR et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J. Infect. Dis.201(9), 1353–1360 (2010).
   PubMedGoogle Scholar
• von Krempelhuber A, Vollmar J, Pokorny R et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine28(5), 1209–1216 (2010).
   PubMed Web of Science ®Google Scholar
• Meisinger-Henschel C, Schmidt M, Lukassen S et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol.88(12), 3249–3259 (2007).
   PubMedGoogle Scholar
• Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol.79(5), 1159–1167 (1998).
   PubMed Web of Science ®Google Scholar
• Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology238(2), 198–211 (1997).
   PubMed Web of Science ®Google Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA89(22), 10847–10851 (1992).
   PubMed Web of Science ®Google Scholar
• Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J. Leukoc. Biol.58(1), 1–13 (1995).
   PubMedGoogle Scholar
• Gomez CE, Najera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther.8(2), 97–120 (2008).
   PubMed Web of Science ®Google Scholar
• Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines7(7), 889–893 (2008).
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin. Biol. Ther.8(12), 1947–1953 (2008).
   PubMed Web of Science ®Google Scholar
• Damon IK, Davidson WB, Hughes CM et al. Evaluation of smallpox vaccines using variola neutralization. J. Gen. Virol.90(Pt 8), 1962–1966 (2009).
   PubMedGoogle Scholar
• Greenberg R, Von Krempelhuber A, Arndtz N et al. The third generation smallpox vaccine IMVAMUNE®: update on the clinical immunogenicity. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, AZ. (2010).
   Google Scholar
• Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl Acad. Sci. USA79(23), 7415–7419 (1982).
   PubMed Web of Science ®Google Scholar
• Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl Acad. Sci. USA79(16), 4927–4931 (1982).
   PubMed Web of Science ®Google Scholar
• Johnston JB, McFadden G. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol.6(8), 695–705 (2004).
   PubMed Web of Science ®Google Scholar
• Pastoret PP, Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol. Infect.116(3), 235–240 (1996).
   PubMed Web of Science ®Google Scholar
• Hanlon CA, Niezgoda M, Hamir AN, Schumacher C, Koprowski H, Rupprecht CE. First North American field release of a vaccinia-rabies glycoprotein recombinant virus. J. Wildl. Dis.34(2), 228–239 (1998).
   PubMed Web of Science ®Google Scholar
• Slate D, Algeo TP, Nelson KM et al. Oral rabies vaccination in North America: opportunities, complexities, and challenges. PLoS Negl. Trop. Dis.3(12), e549 (2009).
   PubMed Web of Science ®Google Scholar
• Human vaccinia infection after contact with a raccoon rabies vaccine bait – Pennsylvania, 2009. MMWR Morb. Mortal. Wkly Rep.58(43), 1204–1207 (2009).
   PubMedGoogle Scholar
• Rupprecht CE, Blass L, Smith K et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med.345(8), 582–586 (2001).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol.28(7), 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Hanke T, Goonetilleke N, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol.88(Pt 1), 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol.85(Pt 4), 911–919 (2004).
   PubMed Web of Science ®Google Scholar
• Cebere I, Dorrell L, McShane H et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime–boost regime to healthy HIV-1-uninfected volunteers. Vaccine24(4), 417–425 (2006).
   PubMed Web of Science ®Google Scholar
• Guimaraes-Walker A, Mackie N, McCormack S et al. Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime–boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine26(51), 6671–6677 (2008).
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Moore S, Dally L et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime–boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol.80(10), 4717–4728 (2006).
   PubMed Web of Science ®Google Scholar
• Dorrell L, Yang H, Ondondo B et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J. Virol.80(10), 4705–4716 (2006).
   PubMedGoogle Scholar
• Goepfert PA, Elizaga M, Sato A et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis.203(5), 610–619 (2011).
   PubMed Web of Science ®Google Scholar
• Ibanga HB, Brookes RH, Hill PC et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect. Dis.6(8), 522–528 (2006).
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med.10(11), 1240–1244 (2004).
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, Vuola JM et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Sci. USA102(13), 4836–4841 (2005).
   PubMed Web of Science ®Google Scholar
• Bejon P, Mwacharo J, Kai O et al. A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials1(6), e29 (2006).
   PubMedGoogle Scholar
• Bejon P, Ogada E, Mwangi T et al. Extended follow-up following a Phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE2(1), e707 (2007).
   PubMed Web of Science ®Google Scholar
• Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin. Biol. Ther.10(2), 281–287 (2010).
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol.9(6), 533–542 (2008).
   PubMed Web of Science ®Google Scholar
• Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev.21(2–3), 103–117 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol.24, 175–208 (2006).
   PubMed Web of Science ®Google Scholar
• Smith CL, Dunbar PR, Mirza F et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer113(2), 259–266 (2005).
   PubMed Web of Science ®Google Scholar
• Dangoor A, Lorigan P, Keilholz U et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol. Immunother.59(6), 863–873 (2010).
   PubMed Web of Science ®Google Scholar
• Smith CL, Mirza F, Pasquetto V et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol.175(12), 8431–8437 (2005).
   PubMed Web of Science ®Google Scholar
• Garber DA, O’Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS ONE4(5), e5445 (2009).
   PubMed Web of Science ®Google Scholar
• Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology188(1), 217–232 (1992).
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis.177(6), 1664–1673 (1998).
   PubMed Web of Science ®Google Scholar
• Bart PA, Goodall R, Barber T et al. EV01: a Phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine26(25), 3153–3161 (2008).
   PubMed Web of Science ®Google Scholar
• Sheppard NC, Bates AC, Sattentau QJ. A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C. AIDS21(4), 524–527 (2007).
   PubMedGoogle Scholar
• McCormack S, Stohr W, Barber T et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine26(25), 3162–3174 (2008).
   PubMed Web of Science ®Google Scholar
• Harari A, Bart PA, Stohr W et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med.205(1), 63–77 (2008).
   PubMed Web of Science ®Google Scholar
• Levy Y, Ellefsen K, Stöehr W et al. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Results of the randomized multicentre EV03/ANRS Vac20 Phase I/II Trial. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16–19 February 2010.
   Google Scholar
• Asmuth DM, Brown EL, DiNubile MJ et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime–boost regimens. J. Infect. Dis.201(1), 132–141 (2010).
   PubMed Web of Science ®Google Scholar
• Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum. Vaccin.5(12), 867–871 (2009).
   PubMed Web of Science ®Google Scholar
• Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des. Devel. Ther.4, 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Gomez CE, Najera JL, Jimenez EP et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine25(15), 2863–2885 (2007).
   PubMed Web of Science ®Google Scholar
• Mooij P, Balla-Jhagjhoorsingh SS, Koopman G et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J. Virol.82(6), 2975–2988 (2008).
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361(23), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Greenough TC, Cunningham CK, Muresan P et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine26(52), 6883–6893 (2008).
   PubMed Web of Science ®Google Scholar
• Harrer E, Bauerle M, Ferstl B et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther.10(2), 285–300 (2005).
   PubMed Web of Science ®Google Scholar
• Ramanathan VD, Kumar M, Mahalingam J et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res. Hum. Retroviruses25(11), 1107–1116 (2009).
   PubMed Web of Science ®Google Scholar
• Currier JR, Ngauy V, de Souza MS et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS ONE5(11), e13983 (2010).
   PubMed Web of Science ®Google Scholar
• Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled Phase III study. Clin. Cancer Res.16(22), 5539–5547 (2010).
   PubMed Web of Science ®Google Scholar
• Harrop R, Shingler W, Kelleher M, de Belin J, Treasure P. Cross-trial analysis of immunologic and clinical data resulting from Phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J. Immunother.33(9), 999–1005 (2010).
   PubMed Web of Science ®Google Scholar
• Carvajal AA, de la Garza A, Cruz Quiroz BJ et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a Phase I/II study. BioDrugs21(1), 47–59 (2007).
   PubMedGoogle Scholar
• Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther.13(6), 592–597 (2006).
   PubMed Web of Science ®Google Scholar
• Berthoud TK, Hamill M, Lillie PJ et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis.52(1), 1–7 (2011).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Pazdur M, Skarupa L, Rauckhorst M, Gulley JL. A randomized Phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin. Breast Cancer7(2), 176–179 (2006).
   PubMed Web of Science ®Google Scholar